Panacea Index Logo

Command Palette

Search for a command to run...

Utility of a Patient-Reported Symptom and Functioning Assessment Tool for Geriatric Oncology Care in China.

Value in health regional issues
May 1, 2022
Dong Xue et al. (5 authors)
Journal ArticleMulticenter StudyHuman Study
Study Details

Study Goal

The researchers aimed to evaluate the reliability and validity of the MD Anderson Symptom Inventory (MDASI) for assessing symptom burden and functional status, including walking interference, in older Chinese cancer patients.

Results Summary

The study found that moderate to severe interference with walking on the MDASI accurately indicated poor performance status and lack of independence in Activities of Daily Living, with an area under the curve of 0.7969 and 0.8304, respectively.

Population

Chinese patients with cancer aged 65 years and older (n = 779, divided into younger [65-74 years] and older [75-84 years] groups).

Effective Dosage

Not available

Duration

Not specified

Interactions

None mentioned

Extracted Claims (16)
InterventionDirectionEndpointPopulationDosageImpactClaim #
MD Anderson Symptom Inventory (MDASI)
no change
symptom burden and functional status
Chinese patients with cancer aged 65 years and older
-
is psychometrically reliable, valid, and clinically sensitive for the measuring
#1
MD Anderson Symptom Inventory (MDASI)
no change
multiple symptoms and physical functioning outcomes
geriatric oncology practice
-
could be adopted to measure
#2
MD Anderson Symptom Inventory (MDASI)
no change
treatment benefits
-
-
could be adopted for research on
#3
-
increase
difficulty remembering
older group (75-84 years old)
effect size 0.32
reported a more severe
#4
-
increase
shortness of breath
older group (75-84 years old)
effect size 0.20
reported a more severe
#5
-
increase
interference with general activity
older group (75-84 years old)
effect size 0.14
reported a more severe
#6
-
decrease
physical functioning
older group (75-84 years old)
effect size -0.33
with significantly worse
#7
-
decrease
cognitive functioning
older group (75-84 years old)
effect size 0.20
with significantly worse
#8
MDASI measures of the core symptoms
no change
reliability
younger group (65-74 years old)
0.90
Cronbach α coefficients were
#9
MDASI measures of total interference with daily activity
no change
reliability
younger group (65-74 years old)
0.93
Cronbach α coefficients were
#10
MDASI measures of the core symptoms
no change
reliability
older group (75-84 years old)
0.93
Cronbach α coefficients were
#11
MDASI measures of total interference with daily activity
no change
reliability
older group (75-84 years old)
0.94
Cronbach α coefficients were
#12
MDASI moderate to severe interference with general activity
no change
poor performance status
-
area under the curve 0.8089
accurately indicated
#13
MDASI moderate to severe interference with walking
no change
poor performance status
-
area under the curve 0.7969
accurately indicated
#14
MDASI moderate to severe interference with general activity
no change
lack of independence status of Activities of Daily Living
-
area under the curve 0.7993
accurately indicated
#15
MDASI moderate to severe interference with walking
no change
lack of independence status of Activities of Daily Living
-
area under the curve 0.8304
accurately indicated
#16
Abstract

OBJECTIVES: Symptom and functional assessment is challenging in geriatric oncology care. This multicenter cross-sectional study examined the use of a multiple-symptom assessment tool, the MD Anderson Symptom Inventory (MDASI), on Chinese patients with cancer aged 65 years and older. METHODS: Patient-rated symptoms and functioning were assessed using MDASI and the European Organization for Research and Treatment of Cancer quality-of-life questionnaire. RESULTS: The most severe symptoms were fatigue and poor appetite. The older group (75-84 years old, n = 224) reported a more severe difficulty remembering (effect size [ES] 0.32; P < .001), shortness of breath (ES 0.20; P = .020), and interference with general activity (ES 0.14; P = .027), with significantly worse physical functioning (ES -0.33; P < .001) and cognitive functioning on the European Organization for Research and Treatment of Cancer quality-of-life questionnaire (ES 0.20; P < .001) than the younger group (65-74 years old, n = 555). For MDASI measures of the core symptoms and total interference with daily activity, Cronbach α coefficients were 0.90 and 0.93, respectively, for the younger group; and 0.93 and 0.94 for the older group, respectively. Moderate to severe (score ≥4) interference with general activity and walking on MDASI accurately indicated poor performance status (area under the curve 0.8089 and 0.7969, respectively) and lack of independence status of Activities of Daily Living (area under the curve 0.7993 and 0.8304, respectively). CONCLUSIONS: MDASI is psychometrically reliable, valid, and clinically sensitive for the measuring symptom burden and functional status of Chinese patients with cancer aged 65 years and older. MDASI could be adopted to measure multiple symptoms and physical functioning outcomes in geriatric oncology practice as well as for research on treatment benefits.

Medical Subject Headings (MeSH)
Activities of Daily LivingAgedAged, 80 and overChinaCross-Sectional StudiesHumansNeoplasmsPatient Reported Outcome Measures
Study Links
Quality Scores
SafetyNot Assessed
Efficacy75/10
Quality85/10
0
Research Impact Scores
APT Score0.05
Weight Score2.21
Normalized Score0.67
Related Supplements